Recent News

• 11.10.2025 - Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
• 11.10.2025 - Voyager Reports Third Quarter 2025 Financial and Operating Results
• 10.06.2025 - Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
• 10.06.2025 - Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
• 09.23.2025 - Neurocrine Biosciences Presents New Post-Hoc Analysis: Treatment with INGREZZA® (valbenazine) Capsules Achieves Earlier Remission of Tardive Dyskinesia Symptoms While Reducing Patient-Reported Disease Burden
• 09.22.2025 - Neurocrine Biosciences Presents Positive New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder
• 09.16.2025 - Danielle Brill
• 09.16.2025 - Cory Kasimov
• 09.16.2025 - Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
• 09.16.2025 - Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025

Recent Filings

• 11.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.05.2025 - 144 Report of proposed sale of securities
• 11.05.2025 - 144 Report of proposed sale of securities
• 11.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.28.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.28.2025 - 8-K Current report
• 10.28.2025 - EX-99.1 EX-99.1
• 09.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 09.03.2025 - 4 Statement of changes in beneficial ownership of securities